BioAge Labs (NASDAQ:BIOA) Stock Rating Reaffirmed as Buy by BTIG Research

BioAge Labs (NASDAQ:BIOA)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a research report issued to clients and investors on Monday, Benzinga reports.

A number of other research analysts have also recently commented on BIOA. Needham & Company LLC decreased their price objective on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Roth Capital restated a “buy” rating and issued a $25.00 target price on shares of BioAge Labs in a research report on Wednesday, September 9th. Wall Street Zen cut BioAge Labs from a “sell” rating to a “strong sell” rating in a report on Saturday, October 10th. Weiss Ratings upgraded shares of BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. Finally, Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a research report on Friday, July 31st. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioAge Labs currently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

BioAge Labs Price Performance

Shares of BIOA stock opened at $5.34 on Monday. The company has a market capitalization of $245.11 million, a PE ratio of -2.09 and a beta of 1.19. The firm’s 50-day moving average is $6.99 and its two-hundred day moving average is $15.48. BioAge Labs has a 12 month low of $4.81 and a 12 month high of $25.95.

BioAge Labs (NASDAQ:BIOA) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.05). The firm had revenue of $0.30 million during the quarter. BioAge Labs had a negative net margin of 1,253.60% and a negative return on equity of 31.42%. Sell-side analysts forecast that BioAge Labs will post -2.49 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new stake in shares of BioAge Labs in the second quarter valued at about $84,000. State of Wyoming purchased a new position in shares of BioAge Labs during the second quarter worth about $154,000. The Manufacturers Life Insurance Company acquired a new position in BioAge Labs in the 2nd quarter valued at about $234,000. Bank of Nova Scotia acquired a new position in BioAge Labs in the 1st quarter valued at about $180,000. Finally, Engineers Gate Manager LP purchased a new stake in BioAge Labs during the 2nd quarter valued at approximately $344,000.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.